重组抗人CD32单抗(IV.3) | Syd Labs PA007392.h1Fs
体内实验级重组抗人CD32单克隆抗体，小鼠IgG2b Kappa（克隆号：IV.3，Syd Labs货号：PA007392.m2b），纯度>95%，适用于体外和体内研究，比如人源化小鼠体内FcγRIIA阻断。不变区为小鼠Mouse IgG2b Kappa (mIgG2b或m2b)，可与重组小鼠IgG2b同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007392.h1Fs |
|---|---|
| 产品名称 | 重组抗人CD32单抗(IV.3) | Syd Labs PA007392.h1Fs |
| 英文名 | In Vivo Grade Recombinant Anti-human CD32 Monoclonal Antibody, Human IgG1 Fc Silent Kappa (Clone: IV.3) |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 分化簇32、FcγRIIA和FcγRIIB |
| 概述 | 人CD32 Fc 阻断抗体 (IV.3 Fc 阻断抗体) 是一种用于人 FcR 阻断试剂的抗人 Fc 受体抗体。Syd Labs提供不同的同种型用于某些应用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | IV.3 |
| 同种型 | 人 IgG1 Kappa |
| 免疫源 | 抗人CD32单克隆抗体（克隆：IV.3）在哺乳动物细胞中产生 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD32单克隆抗体，人IgG1 Fc Silent Kappa(克隆号IV.3)用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007392.h1Fs Syd LabsCD32（克隆IV.3）和抗人CD16（克隆3G8）：用于流式细胞术、免疫组织化学（IHC）和免疫沉淀（IP）。它对FcγRII（CD32）和FcγRIII（CD16）具有高度特异性，并可减少背景染色；它可能不会阻断所有Fc受体。克隆10.1和22或者H22是流式细胞术和功能测定中用于Fc阻断的最广泛的抗人FcγRI（CD64）克隆。它可以阻止非特异性Fc受体与单核细胞、巨噬细胞和树突状细胞结合，提高抗体特异性。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA，流式细胞术，中和，功能测定，如生物分析 PK 和 ADA 测定，以及用于研究受人 CD32 蛋白影响的生物途径的测定。人 Fc 受体阻断剂和人 Fc 受体阻断抗体。 |
文献
抗人CD32单克隆抗体，体内实验级重组，人IgG1 Fc Silent Kappa (克隆号IV.3)（In Vivo Grade Recombinant Anti-human CD32 Monoclonal Antibody, Human IgG1 Fc Silent Kappa (Clone: IV.3)，货号：PA007392.h1Fs Syd Labs）
重组IV.3抗体（IV.3抗体、抗人CD32单抗IV.3）与人CD32（FcγRII或FCGR2）结合。CD32是一种分化簇分子，存在于多种免疫细胞表面。CD32是属于Ig基因超家族的表面受体糖蛋白，对单体形式IgG抗体的Fc区亲和力较低，但对IgG免疫复合物亲和力较高。CD32具有两大主要功能：调节细胞应答和摄取免疫复合物。CD32包括Fc受体FcγRIIa（CD32a）、FcγRIIb（CD32b）和FcγRIIc（CD32c）。
抗人CD32单抗(IV.3)部分引用文献:
1. Receptor transfer between immune cells by autoantibody-enhanced, CD32-driven trogocytosis is hijacked by HIV-1 to infect resting CD4 T cells.
Lu, et al. Cell Rep. 2024 Apr 23;43(4):113994. PMID: 38555986
“Trogocytosis is an intercellular communication process where immune cells extract surface molecules from interacting cells, but its exploitation by viral pathogens remains incompletely understood. …We demonstrate that HIV-1 exploits autoantibody-enhanced, CD32-driven trogocytosis to facilitate the infection of resting CD4+ T cells, a major viral reservoir. …Blocking the CD32 receptor with the anti-CD32 monoclonal antibody clone IV.3 significantly reduced this receptor transfer and subsequent viral entry, highlighting CD32’s role in HIV pathogenesis.”
2. CD32 Ligation Promotes the Activation of CD4+ T Cells.
Holgado, et al. Front Immunol. 2018 Nov 27;9:2814. PMID: 30542352
“The Fc gamma receptor IIa (CD32a) is classically known to be expressed on myeloid cells, but its potential functional role on T cell subsets remains poorly defined. …This study reveals that CD32 is highly expressed on a distinct subset of activated CD4+ T cells and that its ligation provides potent costimulatory signals. …Cross-linking CD32 using the specific monoclonal antibody clone IV.3 enhanced T cell proliferation, activation marker expression, and effector cytokine production.”
3. Inhibition of immunoglobulin E synthesis through Fc?RII (CD32) by a mechanism independent of B-cell receptor co-cross-linking.
Qiao, et al. Immunology. 2006 Nov;119(3):418-25. PMID: 16939665
“The inhibitory receptor Fc?RIIb (CD32) is well documented to downregulate B cell responses when co-cross-linked with the B cell antigen receptor (BCR). …We investigated whether CD32 ligation could inhibit IgE synthesis independently of BCR co-ligation, providing an alternative pathway for allergic modulation. …By utilizing the CD32-specific antibody clone IV.3, we demonstrated a profound suppression of IL-4-induced IgE production in human B cells without the need for BCR engagement.”
4. Important roles of CD32 in promoting suppression of IL-4 induced immune responses by a novel anti-IL-4R? therapeutic antibody.
Wang, et al. Sci Rep. 2019 Jun 28;9(1):9407. PMID: 31253816
“Therapeutic antibodies targeting the IL-4 receptor alpha (IL-4R?) are highly effective in treating type 2 allergic inflammatory diseases, but their optimal function may depend on Fc-gamma receptor interactions. …We show that the suppressive activity of a novel anti-IL-4R? therapeutic antibody is significantly enhanced in the presence of CD32-expressing immune cells. …The essential role of CD32 engagement was confirmed by blocking the receptor with the anti-CD32 clone IV.3, which diminished the therapeutic efficacy of the antibody in vitro.”
5. Platelet?activating immune complexes identified in critically ill COVID?19 patients suspected of heparin?induced thrombocytopenia.
Brodard, et al. J Thromb Haemost. 2021 May;19(5):1321-30. PMID: 33544970
“Severe COVID-19 is frequently complicated by coagulopathy and atypical thrombotic events that clinically mimic heparin-induced thrombocytopenia (HIT). …We identified the presence of circulating immune complexes in critically ill COVID-19 patients that strongly activate platelets directly via the low-affinity IgG receptor Fc?RIIa (CD32a). …The addition of the CD32-blocking monoclonal antibody clone IV.3 completely abolished the platelet activation induced by patient sera, confirming an Fc-dependent mechanism of thrombosis.”